Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tandem Auto-Allo HSCT for Relapsed/Refractory Lymphoma
NCT00005803Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Sep 1999
- Primary completion
- Jan 2016
- Modality
- Stem Cell Therapies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of peripheral blood stem cells in lymphoma, Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL) and 3 more, sponsored by Fred Hutchinson Cancer Center. Primary endpoints: Engraftment of HLA Identical PBSC Allografts at Day 56 and Non-Relapse Mortality at Day 100. Started Sep 1999; status: completed.
02
Drugs
peripheral blood stem cells
03
Conditions
lymphomaHodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)chronic lymphocytic leukemia (CLL)prolymphocytic leukemia (PLL)
Beyond the preview
Go deeper on NCT00005803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005803.